This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Wins FDA Nod for New Clinician Programmer
by Zacks Equity Research
Medtronic's (MDT) latest FDA nod likely to boost Pain Therapies division.
5 Reasons Why You Should Offload Wright Medical Stock Now
by Zacks Equity Research
Foreign currency fluctuations and pricing pressure continue to be major headwinds for Wright Medical Group (WMGI).
Medtronic's ITB Therapy Superior to CMM for PSS Reduction
by Zacks Equity Research
Medtronic (MDT) consistently tries efforts to boost Pain Therapies division, part of the Restorative Therapies Group.
Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Express Scripts 90-Day Analysis of Opioid Management Positive
by Zacks Equity Research
Express Scripts (ESRX) addresses the national opioid epidemic by reducing excessive and improper opioid use.
Henry Schein (HSIC) Buys ABASE, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.
Will Envision Healthcare's Growth Strategies Help the Stock?
by Zacks Equity Research
Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.
Universal Health Grows Inorganically, Rising Costs a Drag
by Zacks Equity Research
Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.
Cerner Gains Momentum in HCIT Space Amid Tough Competition
by Zacks Equity Research
Cerner (CERN) continues to benefit from the ongoing demand for its core solutions and services driven by the HITECH Act.
Abaxis Well Poised on Solid Prospects, Competition Rife
by Zacks Equity Research
Abaxis' (ABAX) new sales and marketing strategies boost investors' confidence.
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Positive tidings on the regulatory front drive IRadimed's (IRMD) growth. The company's solid guidance is also encouraging.
4 Reasons Why Envision Healthcare (EVHC) Looks Dull
by Zacks Equity Research
Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.
Amedisys (AMED) Banks on Personal Care Amid Margin Woes
by Zacks Equity Research
Amedisys' (AMED) efforts have helped turn around the Personal Care business.
Envision Healthcare Down More Than 50% This Year, Here's Why
by Zacks Equity Research
Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Why Envision Healthcare (EVHC) Could Be Positioned for a Slump
by Zacks Equity Research
Envision Healthcare (EVHC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
by Zacks Equity Research
Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.
Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.
Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
What's in Store for Madrigal (MDGL) This Earnings Season?
by Zacks Equity Research
Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.